- Report: Biotech industry raised $1.2B in Q3 venture funding
Venture capital investments in the biotechnology sector jumped by 64% to $1.2 billion while the number of biotech-related deals increased by 22% to 116 during the third quarter of 2012, according to the quarterly MoneyTree Report. Overall venture funding in the life sciences industry, however, dropped 19% in dollars and 12% in terms of the number of deals during the first three quarters of 2012 compared with the same period last year. Patent Docs blog (10/30)       | Meetings, Earning, Markets Canceled Ahead of 'Frankenstorm' | | Pfizer Inc. and Vertex Pharmaceuticals Inc. each postponed earnings reports due to disruptions in transit and other preparations for Hurricane Sandy, a tropical storm of unprecedented size and strength complicated by a number of other meteorological events. Find out the details. |  |
| Health Care & Policy |  |  | | - Millennium-Seattle's lymphoma drug gets conditional EU approval
Millennium: The Takeda Oncology Company and Seattle Genetics obtained conditional approval from the European Commission to market Adcetris, or brentuximab vedotin, for adults with relapsed or refractory systemic anaplastic large cell lymphoma, as well as relapsed or refractory CD30-positive Hodgkin lymphoma who have received autologous stem cell transplants or at least two therapies when transplant or chemotherapy aren't appropriate. Seattle will receive $25 million for each approval. Genetic Engineering & Biotechnology News (10/31) - Biogen's hemophilia drug achieves goal in Phase III study
Biogen Idec said its investigational hemophilia A drug controlled 98% of bleeding episodes with only one or two injections a week during a late-stage trial compared with an average of three to four treatments with existing treatments. The company plans to submit the drug for FDA approval before July and to file an application in Europe after a pediatric trial is completed. Reuters (10/31) - Pediatricians express support for embryonic stem cell research
The American Academy of Pediatrics has published a policy statement in the journal Pediatrics expressing support for embryonic stem cell research. "It is anticipated that continued advances will have a substantial impact on the understanding and treatment of pediatric diseases," the group said. In consideration of the debate surrounding the use of the cells, the group said any policy regarding this should note the differing opinions. As an alternative to ESCs, induced pluripotent stem cells show "great promise," the group added. MedPage Today (free registration) (10/30) | Company & Financial News | | | | - Conn. startup raises $6.6M in funding round
New Haven Pharmaceuticals secured $6.6 million in a Series A financing round from private and public investors. NHP utilizes technology licensed from Yale University to develop proprietary prescription pharmaceuticals using existing drugs or active pharmaceutical ingredients that are generally known to be safe. The startup plans to apply for FDA approval next year for a slow-release aspirin product for secondary prevention of stroke and acute cardiovascular events. Mass High Tech (Boston) (10/29)  | First class, non-stop, global connections.
BIO conferences provide strategic access for the biotech community to accelerate business relationships. We catalyze partnerships through our global portfolio of events, including the world's largest biotech gathering, the BIO International Convention. Learn more about BIO events. | | Industry Deals | | | | | Food & Agriculture | | | | - BIO, ASTA closer to framework for seed patent expiration
BIO and the American Seed Trade Association have completed the initial phase of an agreement aimed at creating guidelines on how to handle patent expirations involving biotech seed technology. The accord, once implemented, will support regulatory approvals of biotech seeds in other countries. The Generic Event Marketability and Access Agreement "is an important first step, but the industry must continue moving forward on the second half of the accord, which will ensure seed companies are able to stack with generic traits to create innovative products for farmers," said Paul Schickler, president of DuPont's Pioneer agricultural division. Reuters (10/31) | Industrial & Environmental | | | | - Novozymes to buy 10% stake in Beta Renewables for $116M
Novozymes has agreed to pay about $116 million to acquire a 10% interest in Beta Renewables, which is part of Italy-based Gruppo Mossi and Ghisolfi. Under the deal, Novozymes will become the preferred enzyme provider for Beta Renewables' cellulosic-ethanol facilities. "Novozymes expects Beta Renewables to be able to contract 15-25 new cellulosic biofuel facilities in the next three to five years," the Danish company said. Reuters (10/29)  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter.
| SmartQuote | | | |  | Nature does not equally distribute energy. Some people are born old and tired while others are going strong at 70."
--Dorothy Thompson,
American journalist and radio broadcaster  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Wednesday, October 31, 2012
- Tuesday, October 30, 2012
- Monday, October 29, 2012
- Friday, October 26, 2012
- Thursday, October 25, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment